Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$3.61 USD
+0.21 (6.18%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $3.60 -0.01 (-0.28%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Brokerage Reports
Fate Therapeutics, Inc. [FATE]
Reports for Purchase
Showing records 21 - 40 ( 439 total )
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Financials Reported; Several Catalysts Ahead; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R